• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Login/ Register
  • Editorial Team
  • Get Involved

Exeposé Online

Making the headlines since 1987

Exeposé Online
  • Home
  • News
      • Local
      • COVID-19
      • University News
  • Comment
  • Features
      • National
      • Worldwide
      • Politics
      • Interviews
  • Science
      • News
      • Lite Science
      • Common Misconceptions
      • Environment
      • Health
      • Technology
  • Sport
  • Lifestyle
      • Fashion and Beauty
      • Features
      • Food
      • Wellbeing
      • Sustainability
  • Music
      • Interviews
      • Features
      • Live Reviews
      • Album Reviews
      • Single Reviews
  • Screen
      • Reviews
      • Features
      • Interviews
      • Festivals and Awards
  • Arts + Lit
      • Interviews
      • Features
      • Reviews
      • Creative Writing
  • Amplify
  • International
  • Multilingual
  • News
  • Comment
  • Features
  • Science
  • Tech
  • Sport
  • Lifestyle
  • Music
  • Screen
  • Arts + Lit
  • Amplify
  • International
  • Multilingual
Home / News

Tocilizumab reduces deaths in COVID-19 patients

Tocilizumab reduces deaths in COVID-19 patients

Image: Govenor Tom Wolf

Mar 8, 2021 – by Holly Van Ryssen

Holly Van Ryssen discusses the anti-inflammatory drug found to reduce the risk of death in patients hospitalised with COVID-19.

An anti-inflammatory drug commonly used to treat Rheumatoid Arthritis has been found to reduce the risk of death in patients hospitalised with COVID-19, according to the results of a new study.

The research, which involved both the University of Exeter and the Royal Devon & Exeter NHS Trust, found that tocilizumab reduces the need for a mechanical ventilator. It also found that tocilizumab reduces the time patients must spend in the hospital before they are discharged.

“This trial is a fantastic success story. […]  I now have an extra treatment to offer to the sicker COVID-19 patient who needs oxygen and has inflammation in their lungs. I can offer this to patients knowing there is good evidence that it saves lives, shortens length of stay and reduces the need to move from a medical ward to the ITU, so less people will need to go onto a ventilator”.

Dr. Ray Sheridan, Associate Clinical Professor at the University of Exeter Medical School

Editor: Elen Johnston

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Mar 8, 2021 By Holly Van Ryssen Filed Under: News, COVID-19, Headlines Tagged With: covid-19, deaths, Tocilizumab, reduces, Patients, New treatment

Primary Sidebar

Tweets by ExeposeNews

Contact Us: editors@exepose.com

Since 1987, Exeposé has given a voice to Exeter students. Over the years, the determination and political fervour exhibited by students through Exeposé have helped shape the University we study at today. We have received national recognition for our award-winning campaigns, investigations and surveys, and always strive to provide students with high-quality news, comment and features.

Disclaimer: The opinions expressed in articles and comments do not reflect the views of Exeposé Online or the University of Exeter Student's Guild.

        


© 2022
Website design: Harry Caton and Ellie Cook
Webdesign & development: Harry Caton